Introduction
The scientific community united against a common enemy in 1971 when President Nixon signed a bill initiating the ''War on Cancer,'' which provided funding for scientific research focused on improving our understanding and treatment of cancer. Without doubt, the intervening years were followed by great advances in the elucidation of the molecular mechanisms that regulate growth and death of normal cells, including a deep understanding of how these pathways progressively go awry during the development of cancer. This understanding led to the era of genomically targeted therapies and ''precision medicine'' in the treatment of cancer. Genomically targeted therapies can result in remarkable clinical responses. The ability of cancer cells to adapt to these agents by virtue of their genomic instability and other resistance mechanisms eventually leads to disease progression in the majority of patients nonetheless. Unraveling the mechanisms by which cancer cells become resistant to drugs and developing new agents to target the relevant pathways have become logical next steps in this approach for cancer treatment. However, given the genetic and epigenetic instability of cancer cells, it is likely that each new drug or combination of drugs targeting the tumor cells will meet with more complex mechanisms of acquired resistance. Recent findings suggest that T cells, bearing antigen receptors that are generated by random rearrangement of gene segments, followed by selective processes that result in a vast repertoire of T cell clones, provide sufficient diversity and adaptability to match the complexity of tumors. Discoveries regarding regulation of T cell responses have provided key principles regarding immune checkpoints that are being translated into clinical success, with durable responses and long-term survival greater than 10 years in a subset of patients with metastatic melanoma, as well as yielding promising results in several other tumor types. Now, with the perspective of combining genomically targeted agents and immune checkpoint therapies, we are finally poised to deliver curative therapies to cancer patients. To support this goal and accelerate these efforts, changes in directions of research support and funding may be required.
Precision Medicine: Targeting the Drivers
In the past three decades, enormous strides have been made in elucidating the molecular mechanisms involved in the development of cancer (Hanahan and Weinberg, 2011) . It is now clear that the oncogenic process involves somatic mutations that result in activation of genes that are normally involved in regulation of cell division and programmed cell death, as well as inactivation of genes involved in protection against DNA damage or driving apoptosis (Bishop, 1991; Solomon et al., 1991; Weinberg, 1991; Knudson, 2001) . These genetic links led to the decision early in the war on cancer to undertake sequencing of cancer genomes to provide a comprehensive view of somatic mutational landscapes in cancer and identify possible therapeutic targets. Infrastructure and funding were provided to coordinate the sequencing efforts. It has become apparent that the level of somatic mutations differs widely between and within different tumor types ranging from very low rates in childhood leukemias to very high rates in tumors associated with carcinogens (Alexandrov et al., 2013).
Mutations can be divided into two broad classes: those whose products ''drive'' tumorigenesis in a dominant fashion and ''passengers'' with no obvious role in the tumor causation. The Cancer Genome Atlas (TCGA) projects have enabled identification of many of these mutations Cancer Genome Atlas Research Network, 2014) . This has allowed for the rational design of drugs that target and selectively interfere with oncogenic signaling pathways. This approach has revolutionized cancer medicine by moving away from the ''one size fits all'' approach-for instance, traditional chemotherapy, which attacks all dividing cells, including both cancer-differentiating or regenerating normal cells-to a more personalized strategy of treating patients with a specific drug only if their cancer bears particular molecular mutations that are target of that drug.
As an example of genomically targeted therapies, an inhibitor against BRAF was developed when it was discovered that 40%-60% of cutaneous melanomas carry mutations in BRAF, which induces constitutive activation of the MAPK pathway (Curtin et al., 2005; Davies et al., 2002) . In a randomized phase III trial comparing a BRAF inhibitor (vemurafenib) versus dacarbazine, the vemurafenib treatment group had a response rate of 48% versus 5% in the dacarbazine arm (Chapman et al., 2011) . However, the median duration of response was short, only 6.7 months . Another oncogenic pathway that has been targeted is the tyrosine kinase chromosomal rearrangement, which results in the fusion oncogene EML4-ALK that is found in 5% of NSCLC patients (Soda et al., 2007) . The EML4 fusion partner mediates ligand-independent oligomerization and/or dimerization of anaplastic lymphoma kinase (ALK), resulting in constitutive kinase activity. Standard chemotherapies in this subgroup of patients have been associated with response rates of up to 10% (Hanna et al., 2004) . Crizotinib, a tyrosine kinase inhibitor targeting ALK (Kwak et al., 2010) , was shown to elicit a response rate of 65% with a median duration of response of less than 8 months in a phase III trial (Shaw et al., 2013) . Although there was a significant increase in progression-free survival for patients treated with crizotinib, regrettably, there was no overall survival benefit in the interim analysis. Therefore, although the concept of targeting ''driver mutations'' has great merit and has demonstrated clinical responses, the reality remains that the majority of patients treated with these agents will derive short-term clinical responses with eventual development of resistance mechanisms that lead to disease progression and death.
Mechanisms operative in acquired resistance fall into three main categories: alterations in the targeted gene (as a result of mutation, amplification, or alternative splicing); other changes that do not affect the original target but re-activate the signaling pathway involved (i.e., NRAS and MEK mutations in BRAF mutant melanoma); and changes that activate alternate pathways (such as activation of growth factor receptors). Considerable effort has gone into finding ways to enhance efficacy of genomically targeted therapies. One effort involves multiple agents that target different molecules in the same pathway, such as the combination of a BRAF inhibitor and a MEK-inhibitor (Larkin et al., 2014; Robert et al., 2015a) . This approach helps to reduce compensatory feedback loops, as well as to block the development of resistance due to mutations downstream that pathway. A different strategy consists of blocking parallel pathways to prevent emerging resistance (Martz et al., 2014) . Still, the chief challenge of these combinatorial approaches is the multiplicity of resistance mechanisms and the fact that different mechanisms may be in operation in different cells due to intratumor heterogeneity. Given these observations, it is difficult to envision realistic approaches to effectively overcome the myriad of resistance mechanisms that may arise in the course of cancer treatment. The continued evolvability of the tumor cells and their mechanisms of escape from targeted therapies raise the question as to whether combinations of genomically targeted agents will ever be curative.
Advantages of Mobilizing T Cells for Cancer Therapy
As the knowledge of the intricate biology of cancer has progressed, so has the understanding of the fundamental cellular and molecular mechanisms that orchestrate the interplay of the innate and adaptive arms of the immune system. In a simplistic way, the innate system is composed primarily of cytokines, the complement system, and phagocytes such as macrophages, neutrophils, dendritic cells, and natural killer (NK) cells. Cells of the innate immune system have hard-wired receptors to detect products of infectious microorganisms and dying cells. Macrophages and neutrophils provide an early defense against microorganisms, whereas dendritic cells provide a key interface to the adaptive immune system, composed of B and T cells with their somatically generated, clonally expressed repertoire of antigen receptors.
The understanding of the basic principles governing the controlling immunity provided the rational for the development of powerful strategies to actively engage the immune system for cancer therapy. Strategies to unleash T cells against tumors are particularly compelling, as the activity of these cells presents important features that are advantageous over other cancer therapies. The first is their specificity. T cells express antigen receptors that recognize cell-surface complexes of MHC molecules and peptides sampled from virtually all the proteins in the cell and are not limited to peptide antigens derived from cellsurface molecules. The second feature is memory. Primary T cell responses are generally followed by the production of long-lived memory T cells with accelerated kinetics of secondary response if the antigen recurs. Finally, the T cell response is adaptable and can accommodate not only tumor heterogeneity but also responses to novel antigens expressed by recurring tumors. It has been calculated that the somatic recombination process that generates the antigen receptors of T cells can generate as many as 10 15 different receptors (Davis and Bjorkman, 1988) . Of this theoretical number, each individual human has perhaps 10 9 different receptors. The immense size of the repertoire suggests that the immune system is indeed well equipped to deal with mutability and adaptability of cancer.
Harnessing T Cell Responses to Tumor Antigens
With the advent of genomic and cDNA expression cloning methods and sequencing of peptides eluted from tumor cell MHC molecules, an avalanche of tumor antigens defined by tumor-specific T cells has been identified in both mice and in humans. Most of these are shared between cancer cells of different individuals and fall into four groups: products of oncogenic viruses (Epstein-Barr virus in certain leukemias and human papilloma virus in cervical and some head and neck cancers); antigens related to tissue-specific differentiation molecules (tyrosinase and related proteins in melanoma and prostate-specific antigen and prostatic acid phosphatase in prostate cancer); molecules normally expressed only during fetal development (carcino-embryonic antigen in colon cancer, a-fetoprotein in liver cancer); and cancer-testes (CT) antigens, which are normally expressed during gametogenesis but are found in many cancer cells as a result of changes in epigenetic regulation (MAGE and NY-ESO-1). Additionally, somatic mutations also can result in the generation of tumor-specific peptides with the potential to bind major histocompatibility complex (MHC) molecules and therefore be recognized by the immune system as neoantigens (Sjö blom et al., 2006; Segal et al., 2008) . The analysis of the epitope landscape of breast and colon carcinoma cells revealed that the products of seven to ten mutant genes in colorectal and breast cancer, respectively, have the potential for binding to HLA-A*0201 alone. Because each heterozygote individual carries as many as 6 different HLA class I genes, this means an average of 42-60 potential neoantigens that can be presented to T cells. In support of these estimates, recent studies have demonstrated that neoantigens generated by somatic mutation are recognized by T cells in both mouse and human cancers (Linnemann et al., 2015; Gros et al., 2014; Tran et al., 2014; Gubin et al., 2014) .
At first, as a result of earlier studies identifying shared antigens, the field of cancer immunotherapy became focused on developing therapeutic vaccines to expand T cells against these shared antigens expressed on tumors. Many studies focused on stimulating T cell responses with peptides, proteins, wholetumor cells including those modified to express cytokines, DNA, recombinant viral-based vaccines, or antigen-pulsed dendritic cells given alone or in combination with various adjuvants or cytokines. Although these trials were conducted with the best available science at the time and provided promising anecdotal evidence that induction of immune responses could elicit clinical benefit, they remained largely negative and generally failed to show objective clinical responses (see Rosenberg et al., 2004 for review) . Enthusiasm waned somewhat as the number of failed clinical trials mounted.
Many reasons might have contributed to the failure of these vaccination strategies, including choice of antigen, failure to provide adequate costimulation, or functional inactivation of tumorreactive T cells (Melero et al., 2014) . A number of T-cell-extrinsic suppressive mechanisms such as TGFb, FoxP3 + regulatory T cells (Treg), and tryptophan metabolites (IDO) that can hamper anti-tumor responses have also been identified, and there have been efforts to minimize the suppressive effects of these in pre-clinical and clinical studies.
Unraveling the Complexity of T Cell Activation
Another contributing factor to the failure of earlier cancer vaccine trials was perhaps the lack of understanding and appreciation of the full complexity of cell-intrinsic pathways that regulate T cell activation. By the late 1980s, it was known that simple engagement of peptide/MHC complexes by the antigen receptor is insufficient for activation of T cells and may render them anergic (Jenkins and Schwartz, 1987; Mueller et al., 1989) . In order to become fully activated, T cells must encounter antigen in the context of antigen-presenting cells (APCs) such as dendritic cells, which provide costimulatory signals mediated by B7 molecules (B7-1 and B7-2) that will engage their ligand, CD28, in the T cell (Greenwald et al., 2005) . Thus, T cells specific for a tumor antigen will not be activated by an initial encounter with tumor cells or may even be rendered anergic because, with the exception of a few lymphomas, tumors do not express costimulatory B7 molecules (Townsend and Allison, 1993) . Thus, tumors are essentially invisible to T cells until the T cells are activated as a result of cross-priming by dendritic cells that present tumor antigens acquired from dying tumor cells. Simultaneous recognition of antigen/MHC complexes and costimulatory ligands by T cells initiates a complex set of genetic programs that result in cytokine production, cell-cycle progression, and production of anti-apoptotic factors that result in proliferation and functional differentiation of T cells. Consistent with the importance of both antigen receptor and costimulatory signals in initiating anti-tumor responses, many therapeutic vaccines now incorporate both antigen and dendritic cells or agents that enhance costimulatory signaling. By the mid-90s, it became clear that T cell priming elicits not only programs leading to induction of T cell responses but also a parallel program that will eventually stop the response. The critical inhibitory program is mediated by CTLA-4, a homolog of CD28 that also binds B7-1 and B7-2, although with much greater avidity than that CD28. Expression of the ctla-4 gene is initiated upon T cell activation, and it traffics to and accumulates in the immunological synapse, eventually attenuating or preventing CD28 costimulation by competition for B7 binding and negative signaling (Walunas et al., 1994; Krummel and Allison, 1995) . The fact that ctla-4 knockout mice suffer from a rapid and lethal lymphadenopathy (Waterhouse et al., 1995; Tivol et al., 1995; Chambers et al., 1997 ) speaks for a negative role for CTLA-4 in limiting T cell responses to prevent damage to normal tissues.
Thus, activation of T cells as a result of antigen receptor signaling and CD28 costimulation is followed not only by induction of genetic programs leading to proliferation and functional differentiation but also by induction of an inhibitory program mediated by CTLA-4, which will ultimately stop proliferation. Extrapolating this paradigm to anti-tumor T cell responses, if eradication of the tumor has not been completed by the time that the inhibitory signal of CTLA-4 is triggered, the T cells will be turned off and will be unable to complete the task. Importantly, this also suggests that, after this program is initiated, vaccines used to stimulate antigen receptor signaling may actually serve to strengthen the ''off'' signal as a result of additional induction of ctla-4 expression by antigen receptor signaling. In any event, this suggests the importance of shifting strategies for cancer immunotherapy from activating T cells to unleashing them.
Inactivating the Brakes to Increase Anti-tumor Immunity Consistent with the observations that CD28 and CTLA-4 had opposing effects on T cell responses in vitro, in the late 90s, it was found that, although blocking antibodies to CD28 impaired anti-tumor responses in mice, blocking antibodies to CTLA-4 enhanced anti-tumor responses in mouse tumor models (Leach et al., 1996) . In fact, the treatment of mice with anti-CTLA-4 antibodies as monotherapy results in complete tumor rejection and long-lived immunity. Later on, mechanistic studies revealed that anti-tumor activity was associated with increased ratio of both CD4 and CD8 effector cells to FoxP3 + regulatory T cells (Quezada et al., 2006) . The success of CTLA-4 blockade in these initial studies raised two compelling points. First, because the target molecule was on the T cell and not the tumor cell, it was feasible to imagine that the same strategy would work on many different histologic tumors, as well as on tumors caused by different genetic lesions. Second, taking into consideration that CTLA-4 inhibited CD28-mediated costimulation by a cellintrinsic mechanism (Peggs et al., 2009) , its blockade could allow for enhanced T cell costimulation, which in turn would increase the efficacy of tumor vaccines, as well as agents that kill tumor cells under conditions that promote inflammatory responses. These possibilities were further supported by the results of a series of studies in different mouse models, including the demonstration that blockade of CTLA-4 was not limited to any particular tumor type but was rather broadly effective. CTLA-4 also was able to synergize with a vaccine consisting of tumor cells engineered to express the cytokine GM-CSF to eradicate tumors (Hurwitz et al., 1998; van Elsas et al., 1999) . Finally, CTLA-4 could be combined with local delivery of irradiation, cryoablation, or an oncolytic virus to induce systemic tumor immunity and eradication of distant metastases (Zamarin et al., 2014; Waitz et al., 2012; Tang et al., 2014) . These preclinical studies supported the development of clinical anti-CTLA-4 therapy.
Immune Checkpoint Therapy: The Clinical Success CTLA-4 blockade was translated to the clinic with a fully human antibody to human CTLA-4 (ipilimumab, Medarex, Bristol-Myers Squibb). Tumor regression was observed in phase I/II trials in patients with a variety of tumor types, including melanoma, renal cell carcinoma, prostate cancer, urothelial carcinoma, and ovarian cancer (Yang et al., 2007; Hodi et al., 2008; Carthon et al., 2010; van den Eertwegh et al., 2012) . Two phase III clinical trials with ipilimumab were recently completed in prostate cancer, the first in patients with castrate-resistant prostate cancer who had not received prior chemotherapy treatment and the second in a more advanced disease setting, in which patients with castrate-resistant prostate cancer presented disease that had progressed on chemotherapy treatment. The former trial is yet to be reported. The latter trial reports the lack of statistical significance (p value of 0.053) to indicate a survival benefit for patients who received ipilimumab treatment. However, subset analyses indicate that patients who have favorable clinical characteristics such as lack of liver metastases do benefit from ipilimumab therapy (Kwon et al., 2014) . Two phase III clinical trials with anti-CTLA-4 (ipilimumab) were also conducted in patients with advanced melanoma and demonstrated improved overall survival for patients treated with ipilimumab (Hodi et al., 2010; Robert et al., 2011) . Importantly, these trials indicate long-term durable responses with greater than 20% of treated patients living for more than 4 years, including a recent analysis indicating survival of 10 years or more for a subset of patients (Schadendorf et al., 2015) . The FDA approved ipilimumab as treatment for patients with melanoma in 2011.
The clinical success of anti-CTLA-4 opened a new field termed ''immune checkpoint therapy'' as additional T cell intrinsic pathways were identified and targeted for clinical development (Sharma et al., 2011; Pardoll, 2012) . Another T-cell-intrinsic inhibitory pathway identified after CTLA-4 was that mediated by PD-1 (programmed death 1) and its ligand PD-L1. PD-1 was initially cloned in 1992 in a study of molecules involved in negative selection of T cells by programed cell death in the thymus (Ishida et al., 1992) . Its function as an immune checkpoint was not established until 2000 upon identification of its ligands (Freeman et al., 2000) . PD-L1 was then shown to protect tumor cells by inducing T cell apoptosis (Dong et al., 2002) . Later, preclinical studies in animal models evaluated anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint therapies to treat tumors (Keir et al., 2008) .
Much like CTLA-4, PD-1 is expressed only in activated T cells. However, unlike CTLA-4, PD-1 inhibits T cell responses by interfering with T cell receptor signaling as opposed to outcompeting CD28 for binding to B7. PD-1 also has two ligands, PD-L1 and PD-L2. PD-L2 is predominantly expressed on APCs, whereas PD-L1 can be expressed on many cell types, including cells comprising the immune system, epithelial cells, and endothelial cells. Antibodies targeting PD-L1 have shown clinical responses in multiple tumor types, including melanoma, renal cell carcinoma, non-small-cell lung cancer , and bladder cancer (Powles et al., 2014) . Similarly, phase I clinical trials with a monoclonal antibody against PD-1 demonstrated clinical responses in multiple tumor types, including melanoma, renal cell carcinoma, non-small-cell carcinoma ), Hodgkin's lymphoma (Ansell et al., 2015) , and head and neck cancers (Seiwert et al., 2014, J. Clin. Oncol., abstract) . Recently, a large phase I clinical trial with an anti-PD-1 antibody known as MK-3475 showed response rates of 37%-38% in patients with advanced melanoma, including patients who had progressive disease after prior ipilimumab treatment (Hamid et al., 2013) , triggering the approval of MK-3475 (pembroluzimab, Merck) by the FDA in September 2014. A phase III clinical trial that treated patients with metastatic melanoma with a different anti-PD-1 antibody (nivolumab, Bristol-Myers Squibb, BMS) also demonstrated improved responses and overall survival benefit as compared to chemotherapy treatment (Robert et al., 2015b) . Nivolumab was FDA approved for patients with metastatic melanoma in December 2014. In addition, nivolumab was FDA approved in March 2015 for patients with previously treated advanced or metastatic non-small-cell lung cancer based on a phase III clinical trial, which reported an improvement in overall survival for patients treated with nivolumab as compared to patients treated with docetaxel chemotherapy.
Because CTLA-4 and PD-1 regulate different inhibitory pathways on T cells, combination therapy with antibodies targeting both molecules was tested and found to improve anti-tumor responses in a pre-clinical murine model (Curran et al., 2010) . A recently reported phase I clinical trial with anti-CTLA-4 in combination with anti-PD-1 also demonstrated tumor regression in 50% of treated patients with advanced melanoma, in most cases with tumor regression of 80% or higher . There are ongoing clinical trials with anti-CTLA-4 (ipilimumab, BMS or tremelimumab, MedImmune/Astrazeneca) plus anti-PD-1 or anti-PD-L1 in other tumor types, with preliminary data indicating promising results (Hammers et al., 2014, J. Clin. Oncol., abstract; Callahan et al., 2014, J. Clin. Oncol., abstract) that highlight this combination as an effective immunotherapy strategy for cancer patients.
As with other cancer therapies, immune checkpoint therapies may lead to side effects and toxicities (see Postow et al., 2015; Gao et al., 2015 for recent reviews). Briefly, these side effects consist of immune-related adverse events that are defined by inflammatory conditions, including dermatitis, colitis, hepatitis, pancreatitis, pneumonitis, and hypophysitis. These side effects can be managed and usually involve administration of immunosuppressive agents such as corticosteroids, which do not appear to interfere with clinical benefit that is derived from the immune checkpoint agents. The profile of side effects that occur with both anti-CTLA-4 and anti-PD-1/PD-L1 antibodies is similar; however, the side effects appear to occur more frequently in the setting of anti-CTLA-4 therapy as compared to anti-PD-1 and anti-PD-L1 therapies. The continued success of immune checkpoint therapies in the clinic will require education of the oncology community regarding recognition and treatment of the side effects elicited by these agents.
Novel Immunologic Targets for Cancer Immunotherapy
Although blockade of the CTLA-4 and PD-1/PD-L1 pathways is furthest along in clinical development, it only represents the tip of the iceberg in the realm of potential targets that can serve to improve anti-tumor responses. Ongoing studies on regulation of immune responses have led to the identification of multiple other immunologic pathways that may be targeted for the development of therapies, either as monotherapy or in combination strategies, for the successful treatment of cancer patients. These include immune checkpoints or inhibitory pathways, as well as co-stimulatory molecules, which act to enhance immune responses. A partial list of new immune checkpoints that are being evaluated in pre-clinical tumor models and/or in the clinic with cancer patients includes LAG-3 (Triebel et al., 1990) , TIM-3 (Sakuishi et al., 2010) , and VISTA (Wang et al., 2011) , whereas co-stimulatory molecules include ICOS (Fan et al., 2014) , OX40 (Curti et al., 2013) , and 4-1BB (Melero et al., 1997) .
Of these emerging immune checkpoints, LAG-3 is the furthest along in clinical development with a fusion protein (IMP321, Immuntep) and an antibody (BMS-986016, BMS) in clinical trials. The fusion protein was tested as monotherapy in patients with renal cell carcinoma, which was well tolerated and led to stabilization of disease in some patients (Brignone et al., 2009 ). IMP321 was also tested in combination with paclitaxel chemotherapy in patients with metastatic breast cancer, which led to an objective response rate of 50% (Brignone et al., 2010) . Based on these promising results, a phase III clinical trial is expected to begin accrual in 2015. Other clinical trials are ongoing with an antibody against LAG-3 (BMS-986016), which is also being tested in combination with anti-PD-1 (nivolumab) (NCT01968109, http://www.clinicaltrials.gov). TIM-3 is another immune checkpoint for which agents are being developed for clinical testing. Pre-clinical studies indicate that TIM-3 is coexpressed with PD-1 on tumor-infiltrating lymphocytes, and combination therapy targeting these two pathways improves anti-tumor immune responses (Sakuishi et al., 2010) . Finally, an antibody targeting VISTA was recently shown to improve antitumor immune responses in mice (Le Mercier et al., 2014) , with clinical development soon to follow. Again, these agents represent only a partial list of the immune checkpoint agents that are currently under development for clinical testing, with expectations that they will be tested in combination strategies based on in-depth analyses of human tumors to provide an understanding of co-expression of these, and other immunologic targets, to guide rational combinations.
Regarding the co-stimulatory molecules, OX40 and 41BB, which are members of the TNF-receptor superfamily, are furthest along in clinical development. A murine anti-OX40 antibody, given as a single dose, was tested in a phase I clinical trial and found to have an acceptable safety profile, as well as evidence of anti-tumor responses in a subset of patients (Curti et al., 2013) . Humanized antibodies against OX40 are expected to enter clinical trial in 2015. Anti-41BB (BMS-663513) is a fully humanized monoclonal antibody that has been tested in a phase I/II study in patients with melanoma, renal cell carcinoma, and ovarian cancer, with promising clinical responses, as well as toxicities, especially at higher doses, which led to re-evaluation of the dose and schedule of treatment (Sznol et al., 2008, J. Clin. Oncol., abstract) . Currently, there are five clinical trials with anti-41BB (urelumab, BMS-663513) that are recruiting patients with various tumor types (http://www.clinicaltrials.gov), including combination with anti-PD-1 (nivolumab), with data expected to be presented from these trials during the next 1 to 2 years. The third co-stimulatory molecule is inducible co-stimulator (ICOS), a member of the CD28/B7 family whose expression increases on T cells upon T cell activation. ICOS + effector T cells (Teff), as opposed to ICOS + regulatory T cells (Treg), increase after patients receive treatment with anti-CTLA-4 (Liakou et al., 2008) , correlating with clinical benefit in a small retrospective study (Carthon et al., 2010) . ICOS thus may serves as a pharmacodynamic biomarker to indicate that anti-CTLA-4 has ''hit its target'' enhancing T cell activation (Ng Tang et al., 2013) . Also, the association of agonistic targeting of ICOS and blockade of CTLA-4 can lead to improved anti-tumor immune responses and tumor rejection in mice (Fan et al., 2014) . Anti-ICOS antibodies are expected to enter into clinical trials in 2015. It is likely that combination therapy to simultaneously engage co-stimulatory pathways and limit inhibitory pathways will be a successful path forward to provide clinical benefit. Importantly, based on the profile of toxicities observed to date, it will be critical to closely monitor these combination strategies for potential adjustments of dosage and management of toxicities that may arise.
Reconciliation: Curative Therapeutic Combinations
The last few decades have witnessed the emergence of two effective but fundamentally different strategies for cancer therapy, each with its own strengths and weaknesses. Genomicguided identification of mutations that drive cancer has led to the development of drugs that result in remarkable responses in the majority of patients whose tumors have the targeted lesion, but the responses are relatively short-lived. As was the case with chemotherapies, it is not unreasonable that combinations of genomically targeted agents will be more powerful against cancer than single agents. It is possible that the use of multiple agents may enhance their effectiveness in terms of increasing overall survival. However, the myriad of mechanisms of acquired resistance and the complexity of the target landscape due to inherent genomic instability may prove extremely difficult to overcome through the sole use of genomically targeted strategies, attaining to achieve cure. In contrast, immune checkpoint therapy is inherently multivalent because targeting a single checkpoint can potentially release T cells with specificity for peptides derived from many different antigens present in a tumor, including differentiation, cancer testis, and even neoantigens generated by mutational events inherent in the genomic instability that drives cancer (Snyder et al., 2014; Linnemann et al., 2015) . As a result of the generation of improved anti-tumor T cell responses, immune checkpoint therapy results in durable responses but only in a fraction of patients. As discussed in the previous sections, it is certainly possible to target multiple immune checkpoints with different mechanisms for improved anti-tumor responses in greater numbers of patients. Will patients benefit from combination of these two strategies? Efforts to combine molecularly targeted agents and immunotherapy have already begun. A phase I clinical trial with agents that inhibit receptor tyrosine kinases, sunitinib, or pazopbnib, in combination with anti-PD-1, was recently reported and showed promising overall response rates of 40%-50% in patients with metastatic renal cell carcinoma (RCC) (Amin et al., 2014, J. Clin. Oncol., abstract) . These types of combinations will require further follow-up to evaluate for survival and durability of responses. An area that has not yet received enough attention is the immunological impact of genetically targeted agents. Vemurafenib, an FDA-approved BRAF inhibitor used for the treatment of melanoma, has been shown to increase expression of tumor antigens and MHC molecules (Frederick et al., 2013) , increasing the sensitivity of the tumor cells to immune attack. Vemurafenib also has potent effects on T cells, enhancing the effects of antigen-mediated activation, perhaps as a result of enhanced activation of the MAP kinase pathway after T cell antigen receptor signaling (Atefi et al., 2014) . These data suggest that certain agents may be well suited for combination with immunotherapy. However, a clinical trial testing a BRAF inhibitor (vemurafenib) in combination with anti-CTLA-4 (ipilimumab) was terminated due to hepatotoxicity (Ribas et al., 2013) . A second clinical trial with a BRAF inhibitor (dabrafenib) in combination with anti-CTLA-4 (ipilimumab) is currently ongoing, and preliminary data indicate that this combination appears to be well tolerated (Puzanov et al., 2014, J. Clin. Oncol., abstract) , which highlights the need to consider differences in drugs, dose, and/or schedule when evaluating agents for combination strategies. Understanding how different genetically targeted agents affect the responsiveness to immunotherapy may help guide choices of combinations of drugs.
From a mechanistic perspective, it is possible that combination strategies with immune checkpoint therapies and genomically targeted agents will result in induction of immune memory, leading to more durable control of tumor growth than what is achievable with either modality alone. Genomically targeted therapies with high objective response rates actually could serve as ''cancer vaccines,'' inducing the killing of tumor cells and resulting in the release of tumor antigens and neoantigens, which can then be presented by APCs to tumor-specific T cells (Figure 1 ). These T cells would become activated but also upregulate inhibitory checkpoints such as CTLA-4 and PD-1, which can be blocked with antibodies to permit enhanced anti-tumor T cell responses, including memory T cell responses, to enable long-term control of disease and possible cure. In addition, the use of targeted agents to directly kill tumor cells, with release of tumor antigens, may focus the activated immune response generated by immunotherapy agents on tumor antigens rather than self-antigens expressed on normal tissues, resulting in fewer adverse events. Furthermore, identification of neoantigens may result in the development of personalized vaccines composed of these neoantigens for novel vaccine strategies plus immune checkpoint agents (Gubin et al., 2014; Tran et al., 2014; Linnemann et al., 2015) .
Although it is clear that clinical responses can be elicited with immune checkpoint therapies or genomically targeted agents, it appears that genomically targeted agents alone tend to improve median survival without providing long-term durable responses (Figure 2 , blue line). Targeting immune checkpoints improves median survival but remarkably also provides long-term durable responses, raising the tail of the survival curve (Figure 2 , green line). When combined, these therapies are likely to have an additive or even synergistic therapeutic effect that not only would potentially further improve median survival but would also raise the tail of the survival curve, increasing the number of patients that appreciate long-term clinical benefit (Figure 2, red line) .
A Future of Curative Cancer Therapies
Federal funding for research has been overwhelmingly directed toward genomically targeted therapies as compared to immune checkpoint therapies. The fundamental research that led to the identification of CTLA-4 as an immune checkpoint, as well as the pre-clinical studies showing the potential of its blockade in cancer therapy, were funded by the National Cancer Institute, but since then, there have been no major initiatives to accelerate progress in this area. Given the durability of the responses that have been obtained with immune checkpoint therapies, it seems reasonable also to allocate enough funds and resources to research focused on immune checkpoint therapies and combination therapy of genomically targeted agents and immunotherapy with promising curative potential. Efforts to determine the impact of genomically targeted therapies on the immune system should also be prioritized, as they will help to identify which agents can enhance anti-tumor T cell responses and guide the choice of combinations from the two classes of agents. At this stage, it does not seem a stretch to say that increasing funding to combination therapies will be key to development of new safe treatments that may prove to be curative for many patients with many types of cancer. Depiction of Kaplan-Meier survival curve with genomically targeted agents (blue line) as compared to standard therapies (purple line), indicating an improvement in median overall survival but lack of durable responses; improved median overall survival and durable responses in a fraction of patients treated with immune checkpoint therapy (green line); possibility for improved median overall survival with durable responses for the majority of patients in the setting of combination treatment with genomically targeted agents and immune checkpoint therapy (red line).
